Literature DB >> 8203209

Optokinetic nystagmus elicited by a random dot pattern and a wide interval stripe pattern in normal subjects.

Y Watanabe1, A Ohmura, H Shojaku, K Mizukoshi.   

Abstract

In optokinetic stimulus in practical living conditions, not only the central fovea but also the peripheral retina are strongly stimulated. In order to investigate the influence of this stimulus on the peripheral retina in optokinetic nystagmus (OKN), we tested OKN elicited by a pattern of numerous random dots (ROKN) in 30 normal subjects and compared the results with those of OKN elicited by a wide interval stripe pattern. The most significant difference between the two response patterns was the correlation between slow phase velocity and slow and fast phase amplitude. In ROKN, the nystagmus amplitude was highly correlated with slow phase velocity. On the other hand, in SOKN there were two types of correlation between slow phase velocity and nystagmus amplitude. One indicated low correlation, which was extremely predominant, and the other, high correlation as in ROKN. This tendency was more marked in the fast phase amplitude. Although it is generally accepted that OKN fast phase in SOKN is controlled by voluntary saccade, our results indicate that ROKN is more strongly controlled by reflective resetting eye movements, which is similar to the nystagmus fast phase in vestibular nystagmus.

Entities:  

Mesh:

Year:  1994        PMID: 8203209     DOI: 10.3109/00016489409128311

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  2 in total

1.  The distribution of quick phase interval durations in human optokinetic nystagmus.

Authors:  Jonathan Waddington; Christopher M Harris
Journal:  Exp Brain Res       Date:  2012-10-26       Impact factor: 1.972

2.  A new motor synergy that serves the needs of oculomotor and eye lid systems while keeping the downtime of vision minimal.

Authors:  Mohammad Farhan Khazali; Joern K Pomper; Aleksandra Smilgin; Friedemann Bunjes; Peter Thier
Journal:  Elife       Date:  2016-08-23       Impact factor: 8.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.